ClinicalTrials.gov
ClinicalTrials.gov Menu

National Registry for Egyptian Pediatric Neuromuscular Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02124616
Recruitment Status : Recruiting
First Posted : April 28, 2014
Last Update Posted : April 28, 2014
Sponsor:
Information provided by (Responsible Party):
Sahar M.A. Hassanein, MD, Ain Shams University

April 25, 2014
April 28, 2014
April 28, 2014
April 2014
April 2020   (Final data collection date for primary outcome measure)
Functional motor ability [ Time Frame: 1 year ]
Motor power in acquired acute neuromuscular diseases will be assessed at admission and morbidity and mortality at discharge from hospital. Functional motor ability will be performed every 3 months for children with inherited neuromuscular diseases.
Same as current
No Changes Posted
Cardio-pulmonary function [ Time Frame: 12 months ]
Pulmonary and cardiac function impairment.
Same as current
Not Provided
Not Provided
 
National Registry for Egyptian Pediatric Neuromuscular Diseases
National Registry for Egyptian Pediatric Neuromuscular Diseases
Our aim is to establish multi-center national Egyptian database of information for inherited and acquired neuromuscular diseases in infants and children from 0 to 18 years of age.

Aims: An open-ended multi-center, national Egyptian study to collect and analyze data for children with Neuromuscular Diseases (NMD) inherited NMD (spinal muscular atrophy (SMA), Duchenne/Becker and congenital muscular dystrophies (DMD/BMD, CMD), congenital myopathies, and congenital myasthenic syndromes) and acquired NMD (neuropathies, myasthenia gravis and myositis).

Participants: Eligible infants and children with inherited and acquired neuromuscular diseases.

DESIGN: This study is a prospective cohort study.

Outcome measures: Motor development assessment, respiratory and cardiac examination.

Observational [Patient Registry]
Observational Model: Case-Only
Time Perspective: Prospective
5 Years
Not Provided
Non-Probability Sample
All children from birth to 18 years of age with inherited or acquired neuromuscular diseases.
  • Spinal Muscular Atrophy
  • Muscular Dystrophy
  • Muscle Diseases
  • Myasthenic Syndromes
  • Polyneuropathies
Not Provided
Neuromuscular diseases
Prospective cohort of children with inherited or acquired neuromuscular diseases.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
Same as current
December 2020
April 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Weakness, hypotonia.
  • Nerve conduction study and electromyographic confirmation of lower motor neuron affection.

Exclusion Criteria:

  • Chromosomal diseases.
  • Malformations and deformations.
Sexes Eligible for Study: All
1 Month to 18 Years   (Child, Adult)
No
Contact: Sahar MA Hassanein, MD, PhD 201223183943 saharhassanein@med.asu.edu.eg
Egypt
 
 
NCT02124616
EGYPT PED-NMD 2014
Yes
Not Provided
Not Provided
Sahar M.A. Hassanein, MD, Ain Shams University
Ain Shams University
Not Provided
Study Chair: Sahar MA Hassanein, MD, PhD Pediatric Department, Children's Hospital, Faculty of Medicine, Ain Shams University
Ain Shams University
April 2014